Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

After failed trials, J&J pivots to early-stage Alzheimer's
Reuters
Wednesday, February 13, 2013 - 10:44am
tags:
Alzheimer's disease, JNJ, bapineuzumab
This Obesity Bet Just Became More Attractive
Motley Fool
Wednesday, February 13, 2013 - 10:43am
tags:
obesity, Vivus, Pfizer, Qsymia, Arena Pharmaceuticals
How Much Will Pfizer's New Drugs Contribute To Future Revenue?
Seeking Alpha
Wednesday, February 13, 2013 - 10:41am
tags:
Pfizer
Merck's Crash of a Titan
Motley Fool
Wednesday, February 13, 2013 - 10:29am
tags:
Merck, Singulair
Merck Cuts First-Quarter Forecast on Venezuela Currency
Bloomberg
Wednesday, February 13, 2013 - 10:28am
tags:
Merck, Venezuela
Keryx Pharmaceuticals: In Or Out?
Seeking Alpha
Wednesday, February 13, 2013 - 10:27am
tags:
Keryx, Zerenex, renal disease
What Does Pfizer's 2012 Earnings Tell Us About Its Operations?
Seeking Alpha
Wednesday, February 13, 2013 - 10:26am
tags:
Pfizer, earnings
Allergan and MAP: Pharma Buyout With a 60% Premium
Motley Fool
Wednesday, February 13, 2013 - 10:24am
tags:
Allergan, MAP Pharmaceuticals, M&A
Bayer Seeks Riociguat Approval
Yahoo/Zacks
Wednesday, February 13, 2013 - 10:22am
tags:
Bayer, Riociguat, PAH, pulmonary arterial hypertension
Five Super Ideas in the Healthcare Sector
Motley Fool
Wednesday, February 13, 2013 - 10:21am
tags:
Eli Lilly, Merck, Forest Labs, Regeneron, Seattle Genetics
Agilent forges diagnostic test partnership with Pfizer; follows January deal with Eli Lilly
Yahoo/AP
Wednesday, February 13, 2013 - 10:20am
tags:
Agilent, Pfizer, Eli Lilly, cancer diagnostics, Dako
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Motley Fool
Wednesday, February 13, 2013 - 10:16am
tags:
JNJ, Multiple Myeloma, Velcade, Celgene, Revlimid, AbbVie, ONYX Pharmaceuticals, Bristol-Myers Squibb
Slow approvals put India's drug trials industry at risk
Reuters
Wednesday, February 13, 2013 - 10:14am
tags:
drug approvals, clinical trials, India
Pharmacyclics Gains ‘Breakthrough’ Status for Cancer Drug
Bloomberg
Wednesday, February 13, 2013 - 10:11am
tags:
Pharmacyclics, ibrutinib, JNJ
Promising Italian Biotech With An Upcoming CHMP Meeting
Seeking Alpha
Tuesday, February 12, 2013 - 12:25pm
tags:
CHMP, Gentium
Shire to Forest on Deal List for AstraZeneca: Real M&A
Bloomberg
Tuesday, February 12, 2013 - 12:13pm
tags:
Shire, Forest Labs, AstraZeneca, M&A
Dynavax Options Trade for Heplisav FDA Approval Decision
TheStreet.com
Tuesday, February 12, 2013 - 12:12pm
tags:
FDA, Dynavax, Heplisav
Alimera Sciences: A Sleeping Giant
Seeking Alpha
Tuesday, February 12, 2013 - 12:06pm
tags:
Alimera, diabetic macular edema, flucinolone ocular implant
GSK, others weigh $3-4 billion deal for Brazilian drugmaker: sources
Reuters
Tuesday, February 12, 2013 - 12:04pm
tags:
GSK, M&A, Brazil, Ache Laboratorios Farmaceuticos
Update on Lilly's Tabalumab
Yahoo/Zacks
Tuesday, February 12, 2013 - 11:12am
tags:
Eli Lilly, tabalumab, rheumatoid arthritis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.